

# Multiple Sclerosis Therapeutics

---

Fourth Edition

Edited by

**Jeffrey A. Cohen, MD**

Director, Experimental Therapeutics Program, Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA

**Richard A. Rudick, MD**

Director, Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA



CAMBRIDGE UNIVERSITY PRESS  
Cambridge, New York, Melbourne, Madrid, Cape Town,  
Singapore, São Paulo, Delhi, Tokyo, Mexico City

Cambridge University Press  
The Edinburgh Building, Cambridge CB2 8RU, UK

Published in the United States of America by Cambridge University  
Press, New York

www.cambridge.org  
Information on this title: www.cambridge.org/  
9780521766272

© Cambridge University Press 2011

This publication is in copyright. Subject to statutory exception  
and to the provisions of relevant collective licensing agreements,  
no reproduction of any part may take place without the written  
permission of Cambridge University Press.

First published 2011

Printed in the United Kingdom at the University Press, Cambridge

*A catalog record for this publication is available from the British Library*

*Library of Congress Cataloging in Publication data*  
Multiple sclerosis therapeutics / edited by Jeffrey A. Cohen,  
Richard A. Rudick. – 4th ed.  
p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-521-76627-2 (hardback)

I. Cohen, Jeffrey A. (Jeffrey Alan), 1954– II. Rudick, Richard A.  
III. Title.

[DNLM: 1. Multiple Sclerosis – therapy. 2. Clinical Trials as Topic –  
methods. 3. Magnetic Resonance Imaging. 4. Multiple Sclerosis –  
pathology. 5. Outcome Assessment (Health Care) WL 360]

LC classification not assigned

616.8'34 – dc23 2011030483

ISBN 978-0-521-76627-2 Hardback

Cambridge University Press has no responsibility for the persistence  
or accuracy of URLs for external or third-party internet websites  
referred to in this publication, and does not guarantee that any  
content on such websites is, or will remain, accurate or appropriate.

Every effort has been made in preparing this book to provide accurate  
and up-to-date information which is in accord with accepted  
standards and practice at the time of publication. Although case  
histories are drawn from actual cases, every effort has been made to  
disguise the identities of the individuals involved. Nevertheless, the  
authors, editors and publishers can make no warranties that the  
information contained herein is totally free from error, not least  
because clinical standards are constantly changing through research  
and regulation. The authors, editors and publishers therefore disclaim  
all liability for direct or consequential damages resulting from the use  
of material contained in this book. Readers are strongly advised to pay  
careful attention to information provided by the manufacturer of any  
drugs or equipment that they plan to use.

# Contents

*List of contributors* page viii

*Abbreviations list* xiii

*Foreword* xv

Stephen C. Reingold

*Preface* xvii

## Section I – Introduction

1 **Aspects of multiple sclerosis that relate to experimental therapeutics** 1

Richard A. Rudick and Jeffrey A. Cohen

2 **The pathology of multiple sclerosis** 12

Ranjan Dutta and Bruce D. Trapp

3 **The immunology of multiple sclerosis** 20

Amit Bar-Or and Peter J. Darlington

4 **The genetics of multiple sclerosis** 35

Jorge R. Oksenberg, Sergio E. Baranzini, and Stephen L. Hauser

5 **The epidemiology of multiple sclerosis** 46

Ruth Ann Marrie and Helen Tremlett

## Section II – Clinical trial methodology

6 **Measures of neurological impairment and disability in multiple sclerosis** 56

Gary R. Cutter, Charity J. Morgan, Amber R. Salter, Stacey S. Cofield, and Laura J. Balcer

7 **Assessment of neuropsychological function in multiple sclerosis** 65

Stephen M. Rao

8 **Health-related quality of life assessment in multiple sclerosis** 79

Deborah M. Miller, Michael W. Kattan, and Alex Z. Fu

9 **Measures of acute and chronic lesions visualized by conventional magnetic resonance imaging** 91

Jack H. Simon and Jerry S. Wolinsky

10 **Measures of magnetization transfer** 112

Massimo Filippi, Joseph C. McGowan, and Maria A. Rocca

11 **Measurement of CNS atrophy** 128

Elizabeth Fisher

12 **Axonal pathology in patients with multiple sclerosis: Evidence from in vivo proton magnetic resonance spectroscopy** 150

Sridar Narayanan, Zografos Caramanos, Paul M. Matthews, and Douglas L. Arnold

13 **Imaging of gray matter lesions in multiple sclerosis** 165

Mike P. Wattjes, Jeroen J.G. Geurts, and Frederik Barkhof

14 **Functional imaging in multiple sclerosis** 175

Kyle C. Kern and Nancy L. Sicotte

15 **Diffusion imaging in multiple sclerosis** 186

Stephen E. Jones and Michael D. Phillips

16 **The use of MRI in multiple sclerosis clinical trials** 198

Robert A. Bermel, Elizabeth Fisher, Peter B. Imrey, and Jeffrey A. Cohen

17 **Optical coherence tomography to monitor axonal and neuronal integrity in multiple sclerosis** 213

Kristin M. Galetta and Laura J. Balcer

18 **The process of drug development and approval in the United States, the European Union, and Asia** 225

Nadine Cohen, Ann Dodds-Frerichs, Tammy Phinney, and Paula Sandler

19 **Selection, interpretation, and development of end-points in multiple sclerosis clinical trials** 232

Marc K. Walton

20 **The challenge of demonstrating long-term benefit of disease-modifying therapies in multiple sclerosis** 244

Maria Trojano

- 21 **The growing need for alternative clinical trial designs for multiple sclerosis** 253  
Stephen C. Reingold, Henry F. McFarland, and A. John Petkau
- 22 **Ethical considerations in multiple sclerosis clinical trials** 261  
Aaron E. Miller, Nada Gligorov, and Stephen C. Krieger
- 23 **Pharmacogenomics and related discovery-driven approaches in multiple sclerosis** 272  
Paulo Fontoura and David Leppert
- 24 **Neutralizing antibodies directed against biologic agents to treat multiple sclerosis** 287  
Per Soelberg Sørensen
- Section III – Clinical trials of multiple sclerosis therapies**
- 25 **Interferon beta to treat multiple sclerosis** 300  
Richard A. Rudick
- 26 **Glatiramer acetate to treat multiple sclerosis** 315  
Jenny Guerre and Corey C. Ford
- 27 **Natalizumab to treat multiple sclerosis** 330  
Chris H. Polman, Joep Killestein, and Richard A. Rudick
- 28 **Mitoxantrone to treat multiple sclerosis** 344  
Gilles Edan and Emmanuelle Le Page
- 29 **Cladribine to treat multiple sclerosis** 358  
Gavin Giovannoni and Stuart D. Cook
- 30 **Fingolimod to treat multiple sclerosis** 370  
Jeffrey A. Cohen
- 31 **Dimethyl fumarate to treat multiple sclerosis** 387  
Robert J. Fox and Ralf Gold
- 32 **Alemtuzumab to treat multiple sclerosis** 393  
Orla Tuohy and Alasdair J. Coles
- 33 **Daclizumab to treat multiple sclerosis** 399  
Jaume Sastre-Garriga and Xavier Montalban
- 34 **Laquinimod to treat multiple sclerosis** 405  
Douglas R. Jeffery
- 35 **Teriflunomide to treat multiple sclerosis** 410  
Paul W. O'Connor
- 36 **High-dose methylprednisolone to treat multiple sclerosis** 418  
Robert J. Fox and R. Philip Kinkel
- 37 **Use of immunosuppressants to treat multiple sclerosis** 436  
James M. Stankiewicz and Howard L. Weiner
- 38 **Intravenous immunoglobulin to treat multiple sclerosis** 444  
Franz Fazekas, Siegrid Fuchs, Per Soelberg Sørensen, and Ralf Gold
- 39 **Plasma exchange treatment for CNS inflammatory demyelinating disease** 454  
Brian G. Weinshenker, B. Mark Keegan, Jeffrey L. Winters, Ichiro Nakashima, and Kazuo Fujihara
- 40 **Statins in multiple sclerosis** 465  
Martin S. Weber, Emmanuelle Waubant, and Scott S. Zamvil
- 41 **T-cell-based therapies for multiple sclerosis** 472  
Tanuja Chitnis and Samia J. Khoury
- 42 **B-cell-based therapies for multiple sclerosis** 483  
Emmanuelle Waubant and Amit Bar-Or
- 43 **Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis** 498  
Rhonda R. Voskuhl
- 44 **Hematopoietic stem cell transplantation to treat multiple sclerosis** 508  
Richard K. Burt and Francesca Milanetti
- 45 **Mesenchymal stem cell transplantation to treat multiple sclerosis** 520  
Don Mahad, Sarah M. Planchon, and Jeffrey A. Cohen
- 46 **Neuroprotection in multiple sclerosis** 535  
Avindra Nath and Peter A. Calabresi
- 47 **Combination therapy in multiple sclerosis** 547  
Michelle Fabian and Fred D. Lublin
- 48 **Dalfampridine in multiple sclerosis** 557  
Andrew D. Goodman
- 49 **Complementary and alternative treatments in multiple sclerosis** 562  
Vijayshree Yadav, Lynne Shinto, and Dennis N. Bourdette
- 50 **The role of chronic cerebrospinal venous insufficiency in multiple sclerosis** 574  
Devon Conway, Soo Hyun Kim, and Alexander Rae-Grant

## Section IV – Therapy in clinical practice

- 51 **Disease-modifying therapy for multiple sclerosis in clinical practice** 583  
Jeffrey A. Cohen and Andrew D. Goodman
- 52 **Treatment for patients with primary progressive multiple sclerosis** 604  
Zhaleh Khaleeli and Alan J. Thompson
- 53 **Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders** 614  
Sean J. Pittock
- 54 **Management of pediatric multiple sclerosis** 632  
E. Ann Yeh and Bianca Weinstock-Guttman
- 55 **Use of MRI in the clinical management of multiple sclerosis** 645  
J. Theodore Phillips and Lael A. Stone
- 56 **Multiple sclerosis-associated fatigue** 654  
Lauren B. Krupp and Dana J. Serafin
- 57 **Management of spasticity** 666  
Francois A. Bethoux and Matthew Sutliff
- 58 **Management of bladder and sexual dysfunction in multiple sclerosis** 676  
Natasha Frost, Jessica Szpak, Scott Litwiller, and Alexander Rae-Grant
- 59 **Depression in multiple sclerosis** 696  
Adam I. Kaplin and Ryan E. Stagg
- 60 **Assessment and treatment of pain disorders in multiple sclerosis** 707  
Jahangir Maleki and Amy Sullivan
- 61 **Management of medical comorbidities in patients with multiple sclerosis** 714  
John R. Scagnelli and Myla D. Goldman
- 62 **Rehabilitation in multiple sclerosis** 724  
Francois A. Bethoux and Matthew Sutliff

---

*Index* 731

*Color plates appear between p. 398 and 399*

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.